Effectiveness of an intervention to optimise the use of mirabegron for overactive bladder: a quasi-experimental study in primary care

Overactive bladder is a composite of lower urinary tract storage symptoms. Pharmacological treatment is widely employed despite markedly modest efficacy data, adverse effects, and costs for the health system. To determine the 12-month efficacy of an intervention delivered by GPs on mirabegron revisi...

Full description

Saved in:
Bibliographic Details
Published inBritish journal of general practice Vol. 68; no. 677; pp. e852 - e859
Main Authors Fernández-Liz, Eladio, Tristante, Pere Vivó, Martínez, Antonio Aranzana, Colomer, Maria Estrella Barceló, Rebull, Josep Ossó, Dolcet, Maria Josep López
Format Journal Article
LanguageEnglish
Published England Royal College of General Practitioners 01.12.2018
Subjects
Online AccessGet full text

Cover

Loading…
More Information
Summary:Overactive bladder is a composite of lower urinary tract storage symptoms. Pharmacological treatment is widely employed despite markedly modest efficacy data, adverse effects, and costs for the health system. To determine the 12-month efficacy of an intervention delivered by GPs on mirabegron revision and, if appropriate, discontinuation of treatment. Multicentre, quasi-experimental study in Barcelona (Catalonia), Spain. Two groups composed of 17 intervention and 34 control practices were formed. The follow-up period was 12 months, from 1 January to 31 December 2017. A structured intervention was designed consisting of initiatives with GPs and urology/gynaecology specialists. The primary outcome was mirabegron use at 12 months. Of the 1932 patients, a significant discontinuation in treatment was observed at 12 months' follow-up in the intervention group (IG) ( = 433 out of 762, 56.8%), in contrast with the control one (CG) ( = 484 out of 1170, 41.4%) ( <0.001). There was also a reduced incorporation of new treatments in the IG ( = 214 out of 762, 28.1%) compared with the CG ( = 595 out of 1170, 50.9%) ( <0.001). In relation to patients with treatment at the beginning and end of the period, there was a decrease of 219 (28.7%) patients in the IG and an increase of 111 (9.5%) in the CG ( <0.001). The structured intervention showed optimisation in the use of mirabegron. When considering discontinuation it is necessary to provide clear data on the benefits and/or risks for patients and their caregivers, as such information is a precondition for shared decision making.
Bibliography:ObjectType-Article-1
SourceType-Scholarly Journals-1
ObjectType-Feature-2
content type line 23
ISSN:0960-1643
1478-5242
DOI:10.3399/bjgp18X699953